KTET Answer Key

Intra-Cellular Therapies trades as part of the biotechnology industry and is in the healthcare sector. The company CEO is Sharon Mates. Intra-Cellular Therapies Inc is a biopharmaceutical company. It is engaged in discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders.



Previous Intraday Performance:

The ITCI shares had a previous change of -0.64% which opened at 12.77 and closed at 12.50. It moved to an intraday high of 12.85 and a low of 12.39.

SeekingAlpha:  Intra-Cellular Therapies Inc. (ITCI) CEO Sharon Mates on Q1 2019 Results – Earnings Call Transcript

Historical Performance:

Over the last five trading days, ITCI shares returned -2.87% and in the past 30 trading days it returned -3.33%. Over three months, it changed -7.75%. In one year it has changed -44.74% and within that year its 52 week high was 23.62 and its 52 week low was 10.21. ITCI stock is 22.43% above its 52 week low.

Our calculations result in a 200 day moving average of 15.26 and a 50 day moving average of 12.85. Right now, ITCI stock is trading -18.09% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Intra-Cellular Therapies beats by $0.24

Liquidity:

The company has a market cap of $689.2m with 55.1m shares outstanding and a float of 52.6m shares. Trading volume was 360,361 shares and has experienced an average volume of 325,216 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Intra-Cellular Therapies was -2.84 which ended on 31st of December 2018. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.89.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 05-08-2019: -0.63
4thQtr 2018Reported 02-27-2019: -0.75
3rdQtr 2018Reported 11-07-2018: -0.76
2ndQtr 2018Reported 08-02-2018: -0.68
1stQtr 2018Reported 05-03-2018: -0.65

Base on our calculations, the intrinsic value per share is 223.43, which means it might be undervalued and has a margin of safety of 94.41%.

The long-term trend of the EPS is a vital number as it helps understand the future potential of Intra-Cellular Therapies; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -100.00% over the last twelve months.



Indicators Also to Watch:

Based on the latest filings, there is 4.50% of insider ownership.

The beta was calculated to be 1.30.

SeekingAlpha:  Intra-Cellular Therapies beats by $0.24

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -39.18% and price-to-book is 2.40.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 3  : Valuation Result
 0  : Dividend Safety Result
 3  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here